Adamis Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

CEO

CFO

Adamis Pharmaceuticals has an office in San Diego

San Diego, US (HQ)

300 11682 El Camino Real

Adamis Pharmaceuticals's revenue was reported to be $3 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 3 m |

## Gross profit (Q1, 2017) | 1.4 m |

## Gross profit margin (Q1, 2017), % | 45% |

## EBIT (Q1, 2017) | (5.7 m) |

## Market capitalization (15-Aug-2017) | 123.2 m |

## Cash (31-Mar-2017) | 399.5 k |

Adamis Pharmaceuticals's current market capitalization is $123.2 m.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 6.5 m | ||

## Cost of goods sold | 4.9 m | ||

## Gross profit | 1.6 m | ||

## Gross profit Margin, % | 25% | ||

## R&D expense | 9.7 m | ||

## General and administrative expense | 17.1 m | ||

## Operating expense total | 26.8 m | ||

## EBIT | (4.4 m) | (13.9 m) | (25.2 m) |

## EBIT margin, % | (389%) | ||

## Interest expense | (214.4 k) | ||

## Interest income | 9.3 k | ||

## Income tax expense | 4.6 m | ||

## Net Income | (8.2 m) | (13.6 m) |

USD | Q1, 2014^{} | Q2, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 1.9 m | 2.1 m | 3 m | ||||||

## Cost of goods sold | 1.3 m | 1.8 m | 1.7 m | ||||||

## Gross profit | 582.1 k | 254.5 k | 1.4 m | ||||||

## Gross profit Margin, % | 30% | 12% | 45% | ||||||

## R&D expense | 1.7 m | 597.5 k | 1.4 m | 1.3 m | 1.2 m | 3.4 m | 3.4 m | 1.5 m | 1.5 m |

## General and administrative expense | 1 m | 1.3 m | 2.8 m | 2.3 m | 2.1 m | 2.6 m | 4.6 m | 5.3 m | 5.6 m |

## Operating expense total | 2.8 m | 1.9 m | 4.1 m | 3.5 m | 3.3 m | 6 m | 8 m | 6.8 m | 7.1 m |

## EBIT | (2.8 m) | (1.9 m) | (4.1 m) | (3.5 m) | (3.3 m) | (6 m) | (7.4 m) | (6.6 m) | (5.7 m) |

## EBIT margin, % | (385%) | (317%) | (188%) | ||||||

## Interest expense | (225.9 k) | (145.4 k) | (225.9 k) | (72.4 k) | (70.2 k) | (67.5 k) | |||

## Interest income | 167 | 1.3 k | 4 k |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 5.4 m | 4.1 m | 4.1 m |

## Accounts Receivable | 805.4 k | ||

## Inventories | 14.5 k | 71 k | 942.1 k |

## Current Assets | 4.2 m | ||

## Goodwill | 7.6 m | ||

## Total Assets | 15.1 m | 12.1 m | 37.8 m |

## Accounts Payable | 671 k | 497.8 k | 2.2 m |

## Current Liabilities | 8.6 m | ||

## Total Liabilities | 12.5 m | ||

## Additional Paid-in Capital | 58.3 m | 78.3 m | 113.7 m |

## Retained Earnings | (46.1 m) | (69 m) | (88.5 m) |

## Total Equity | 9.3 m | 25.3 m | |

## Financial Leverage | 1.3 x | 1.5 x |

USD | Q1, 2014^{} | Q2, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 2.1 m | 5.9 m | 11.2 m | 8.5 m | 6.3 m | 4.4 m | 417.1 k | 7.8 m | 399.5 k |

## Accounts Receivable | 744.7 k | 595.6 k | 1.2 m | ||||||

## Inventories | 1.2 m | 1.1 m | 914.2 k | ||||||

## Current Assets | 2.2 m | 6 m | 11.3 m | 8.5 m | 6.4 m | 5 m | 2.6 m | 10.7 m | |

## Goodwill | 2.2 m | 2.2 m | 7.6 m | ||||||

## Total Assets | 11.6 m | 15.1 m | 20 m | 16.9 m | 14.6 m | 12.7 m | 29.4 m | 36.7 m | 33.7 m |

## Accounts Payable | 547.7 k | 750 k | 977.2 k | 498 k | 408.8 k | 1.5 m | 4.2 m | 1.7 m | 2.7 m |

## Current Liabilities | 8.8 m | ||||||||

## Additional Paid-in Capital | 58.7 m | 63.9 m | 76.3 m | 77.1 m | 77.7 m | 84.1 m | 96.2 m | 112.6 m | 115.1 m |

## Retained Earnings | (49 m) | (51.1 m) | (58.6 m) | (62.2 m) | (65.4 m) | (75.4 m) | (81.1 m) | (87.8 m) | (94.2 m) |

## Total Equity | 9.7 m | 12.8 m | 17.7 m | 14.8 m | 12.3 m | 8.7 m | 15 m | 24.8 m | 20.9 m |

## Financial Leverage | 1.2 x | 1.2 x | 1.1 x | 1.1 x | 1.2 x | 1.5 x | 2 x | 1.5 x | 1.6 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Depreciation and Amortization | 888.4 k | 2.5 m | |

## Inventories | 14.5 k | (165 k) | 1.9 k |

## Accounts Payable | 671 k | 116 k | (1.7 m) |

## Cash From Operating Activities | 5.4 m | 306 k | |

## Purchases of PP&E | (121.1 k) | ||

## Cash From Investing Activities | 260.7 k | ||

## Short-term Borrowings | (38.7 k) | ||

## Cash From Financing Activities | 4.8 m | 21.9 m | |

## Interest Paid | 89.4 k | 229.6 k | |

## Income Taxes Paid | 2.4 k | 19 k |

USD | Q1, 2014^{} | Q2, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Accounts Receivable | 744.7 k | 595.6 k | 1.2 m | ||||||

## Inventories | 1.2 m | 914.2 k | |||||||

## Accounts Payable | 547.7 k | 750 k | 977.2 k | 498 k | 408.8 k | 1.5 m | 4.2 m | 1.7 m | 2.7 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 209.5 k |

## Financial Leverage | 1.6 x |

August 29, 2016

When Mylan Pharmaceuticals said Thursday that it would be giving a $300 "savings card" discount to patients buying a two-pack of EpiPens — a prescription with a retail price of around $600 — it didn't do much to fend off ire from politicians and the public.
So, on Monday, th…

August 09, 2016

* Sabby Management, LLC reports 7.73 pct passive stake in
Adamis Pharmaceuticals as of August 3, 2016 - SEC Filing
Source - http://bit.ly/2aJYpKi
Further company coverage:

August 09, 2016

* Sabby Management, LLC reports 7.8 pct passive stake in
Adamis Pharmaceuticals as of August 3, 2016 - SEC Filing
Source - http://bit.ly/2aJYpKi
Further company coverage: